Higher frequency of cagA EPIYA-C Phosphorylation Sites in *H. pylori* strains from first-degree relatives of gastric cancer patients

Dulciene MM Queiroz, Cícero ISM Silva, Maria HRB Goncalves, Manuel B Braga-Neto, Andréa BC Fialho, André MN Fialho, Gifone A Rocha, Andreia MC Rocha, Sérgio A Batista, Richard L Guerrant, Aldo AM Lima and Lucia LBC Braga

**Abstract**

**Background:** To evaluate the prevalence of more virulent *H. pylori* genotypes in relatives of gastric cancer patients and in patients without family histories of gastric cancer.

**Methods:** We evaluated prospectively the prevalence of the infection by more virulent *H. pylori* strains in 60 relatives of gastric cancer patients comparing the results with those obtained from 49 patients without family histories of gastric cancer. *H. pylori* status was determined by the urease test, histology and presence of *H. pylori* ureA. The cytotoxin associated gene (cagA), the cagA-EPIYA and vacuolating cytotoxin gene (vacA) were typed by PCR and the cagA EPIYA typing was confirmed by sequencing.

**Results:** The gastric cancer relatives were significant and independently more frequently colonized by *H. pylori* strains with higher numbers of CagA-EPIYA-C segments (OR = 4.23, 95%CI = 1.53–11.69) and with the most virulent s1m1 vacA genotype (OR = 2.80, 95%CI = 1.04–7.51). Higher numbers of EPIYA-C segments were associated with increased gastric corpus inflammation, foveolar hyperplasia and atrophy. Infection by s1m1 vacA genotype was associated with increased antral and corpus gastritis.

**Conclusions:** We demonstrated that relatives of gastric cancer patients are more frequently colonized by the most virulent *H. pylori* cagA and vacA genotypes, which may contribute to increase the risk of gastric cancer.

**Keywords:** *Helicobacter pylori*, Gastric cancer, *H. pylori* CagA-EPIYA, *H. pylori* vacA

**Background**

*Helicobacter pylori*, a Gram-negative bacterium that infects the stomach of approximately half the world’s population, is associated with the development of gastrointestinal diseases including gastric and duodenal peptic ulcer, distal gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma [1]. It is estimated that individuals infected with *H. pylori* have more than two-fold increased risk of developing gastric cancer compared with non-infected ones [2] although Japanese studies might suggest that nearly all gastric cancer is related to *Helicobacter* [3]. Why only 1 to 5% of *H. pylori*-infected persons develop gastric cancer remains unknown and it seems to depend on the relationship between environmental, host genetics and bacterial virulence factors.

Several studies have shown an increased risk of developing gastric cancer in relatives of patients with the disease [2,4]. Similarly, an increased prevalence of precancerous gastric lesions has been observed in relatives of gastric cancer patients [5]. However, molecular mechanisms by which *H. pylori* triggers the process leading to gastric carcinoma remain largely unknown.

The most investigated *H. pylori* virulence determinant, the cag-PAI (cytotoxin associated gene pathogenicity island), encodes a type IV secretion system (T4SS) that is responsible for the entrance of an effector protein,
CagA, into host gastric epithelial cells [6,7]. Once translocated, CagA localizes to the inner surface of the plasma membrane where it is phosphorylated on the tyrosine residues within phosphorylation motifs in carboxy-terminal variable region of the protein by multiple members of the src-family tyrosine kinases. Once phosphorylated, CagA forms a physical complex with SHP-2 phosphatase and triggers abnormal cellular signals, which enhance the risk of damaged cells acquiring precancerous genetic changes [8,9].

The phosphorylation motifs, defined as a sequence of five amino acids (Glu-Pro-Ile-Tyr-Ala), are classified as EPIYA-A, EPIYA-B, EPIYA-C and EPIYA-D, according to amino acid sequences flanking the motifs. CagA proteins nearly always possess EPIYA-A and -B segments, that are followed by none, one, two or three C segments in strains circulating in the Western countries, or a D segment, in East Asia strains [10,11]. It has also been shown that infection with CagA strains having high number of EPIYA-C segments imparts a greater risk of precancerous gastric lesions and cancer [12-15].

Another virulence factor of H. pylori is a protein known as vacuolating cytotoxin A (VacA), which causes cytoplasmatic vacuolization in gastric epithelial cells, increasing the plasma cell and mitochondrial membrane permeability leading to apoptosis. The production of the cytotoxin is associated with the cag-PAI but depends on the vacA genotype [16-18]. The vacA is a polymorphic gene with two main signal region genotypes s1 and s2, and two different alleles in the mid region of the gene named m1 and m2. Infection with strains possessing the s1m1 genotype has been associated with precancerous gastric hypochlorhydria [17] and gastric carcinoma [19].

In a recent study conducted in Fortaleza, Northeastern, Brazil, in an area of high prevalence of gastric cancer and H. pylori infection, our group has shown a high prevalence of either pangastritis or precancerous lesions in relatives of gastric cancer patients infected with H. pylori [20]. Furthermore, Argent et al., (2008) observed an association between vacA s1m1 genotype of H. pylori strains and low gastric acid secretion in first-degree relatives of gastric cancer patients from Scotland [21]. Otherwise, the authors did not find associations between CagA positive status and or number of tyrosine phosphorylated motifs and gastric lesions in that population.

Since geographical differences have been observed among studies that evaluated association between H. pylori virulence factors and diseases, the aim of this cross-sectional prospective study was to evaluate the CagA EPIYA motifs of H. pylori strains in first-degree relatives of gastric cancer patients comparing the results with those obtained from a control group composed of subjects with no family history of gastric cancer. Because the s1m1 genotype of the vacA H. pylori was seen to be more frequently observed in the strains of gastric cancer patients, we also evaluated the vacA mosaicism in the strains.

Methods
The study was approved by the Ethical Committee of Research of the University of Ceará, and informed consent was obtained from each subject.

Patients
Sixty H. pylori-positive first-degree relatives [42 female; mean age 40.42 ± 11.80; (4 brothers and 13 sisters; mean age 56.24 ± 11.80 years, 14 sons and 29 daughters; mean age 34.51 ± 7.66)] of gastric cancer patients from outpatient follow-up at Walter Cantídio Hospital were invited to participate. The control group was composed of 49 (32 female; mean age 43.20 ± 12.59) H. pylori-positive patients who concurrently underwent upper gastrointestinal endoscopy for investigation of dyspepsia at the same Hospital. They did not have family history of gastric cancer, and were social class matched with the study group. Patients with history of gastric surgery, active gastrointestinal bleeding, use of steroids, immunosuppressive drugs, NSAIDs, proton pump inhibitors or who were treated for H. pylori eradication were excluded from the study. Relatives and controls were not included if they were under 18 or above 81 years old.

Biopsy fragment collection
Gastric fragments were obtained during endoscopy from five different sites as recommended by the Updated Sydney System for classification of gastritis [22]. Additionally, two fragments were collected from the antral mucosa for the rapid urease test and for DNA to investigate the presence of H. pylori genes. H. pylori infection was confirmed by positive results in at least two tests including a rapid urease test, histological analysis and presence of ureA gene of H. pylori.

Histology
Endoscopic biopsy samples of the gastric mucosa were fixed in 10% formalin and embedded in paraffin wax, and 4-μm-sections were stained with hematoxylin-eosin for routine histology. Gastritis was classified according to the Updated Sydney system. The samples of the gastric mucosa were also stained with Giemsa for detection of H. pylori.

DNA extraction
The antral gastric DNA was extracted using the QIAmp (QIAGEN, Hilden, Germany) kit according to the manufacturer’s recommendations with minor modifications [23]. The DNA concentration was determined by
spectrophotometry using NanoDrop 2000 (Thermo Scientific, Wilmington, NC) and stored at −20°C until use.

The presence of *H. pylori* specific *ureA* gene was evaluated according to methodology reported by Clayton *et al.* [24]. The standard Tx30a *H. pylori* strain was used as a positive control, and an *Escherichia coli* strain and distilled water were both used as negative controls.

The thermocycler GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA) was used for all reactions. The amplified products were electrophoresed in 2% agarose gel, stained with ethidium bromide, and analyzed in an ultraviolet light transilluminator.

**vacA and cagA detection**

PCR amplification of the *vacA* signal sequence and mid region was performed by using the oligonucleotide primers described by Atherton *et al.* [15]. The strains were initially classified as type s1 or s2 and type m1 or m2. All *H. pylori* strains with s1 were further characterized into s1a, s1b or s1c [25,26].

The *cagA* gene was amplified by means of two previously described set of primer pairs [27,28]. A *H. pylori* strain from our collection (1010–95), known to be *vacA* s1m1 and *cagA*-positive, was used as a positive control, and the s2m2 *vacA* genotype, *cagA*-negative standard Tx30a *H. pylori* strain and distilled water were both used as negative controls. The *H. pylori* strains were considered to be *cagA*-positive when at least one of the two reactions was positive.

**Amplification of the 3’ variable region of cagA**

For the PCR amplification of the 3’ variable region of the *cagA* gene (that contains the EPIYA sequences), 20 to 100 ng of DNA were added to 1% Taq DNA polymerase buffer solution (KCl 50 mM and Tris–HCl 10 mM, pH, 8.0), 1.5 mM MgCl2, 100 μM of each deoxynucleotide, 1.0 U Platinum Taq DNA polymerase (Invitrogen, São Paulo, Brazil), and 10 pmol of each primer, for a total solution volume of 20 μL. The primers used were previously described by Yamaoka *et al.* [29]. The reaction conditions were: 95°C for 5 minutes, followed by 35 cycles of 95°C for 1 minute, 50°C for 1 minute, and 72°C for 1 minute, and 72°C for 7 minutes. The reaction yielded products of 500 to 850 bp as follows: EPIYA-AB: 500 bp; EPIYA-ABC: 640 bp; EPIYA-ABCC: 740 bp and EPIYA-ABCC: 850 bp (Figure 1).

We also used the method described by Argent *et al.* [30] for the PCR amplification of the 3’ variable region of the *cagA* gene that contains the EPIYA sequences in order to improve the accuracy of our results.

**Sequencing of the 3’ variable region of cagA**

A subset of samples was randomly selected for sequencing in order to confirm the PCR results. PCR products were purified with the Wizard SV Gel and PCR Clean-up System (Promega, Madison, MI) according to the manufacturer’s recommendations. Purified products were sequenced using a BigDye Terminator v3.1 Cycle Sequencing kit in an ABI 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA). The sequences obtained were aligned using the CAP3 Sequence Assembly Program (available from: http://blast.ncbi.nlm.nih.gov/Blast.cgi) and compared to sequences deposited into the GenBank (http://www.ncbi.nlm.nih.gov/Genbank/).

**Statistical analysis**

Data were analyzed with SPSS (Inc. Chicago, IL), version 17.0. The risk of relatives of gastric carcinoma to be infected by more virulent strains, with increased number of EPIYA-C motifs and s1m1 *vacA* genotype, was initially evaluated in univariate analysis. For that, *cagA* strains were stratified in those possessing at least one EPIYA–C segment and those with more than one EPIYA-C segment and the most virulent *vacA* s1m1 genotype was compared with s1m2 plus s2m2. Variables with a *p*-value less than or equal to 0.25 were included in the final model of logistic regression, controlling for the influences of age and sex. Odds Ratio (OR) and 95% confidence intervals (CI) were calculated. The logistic model fitness was evaluated with the Hosmer-Lemeshow test [31]. Association of the number of EPIYA-C segments and the presence of *vacA* virulent genotypes with the degree of gastric inflammation, atrophy and intestinal metaplasia was done by the two-tailed Mann–Whitney Test. The level of significance was set at a *p* value ≤ 0.05.

**Results**

The presence of *H. pylori* specific *ureA* gene was detected in the gastric mucosa of all 109 studied subjects.

**cagA status of the patients**

*cagA* positivity was observed in the gastric fragments from 51 (85.00%) of 60 gastric cancer relatives and in those from 43 (87.76%) of 49 controls, without difference between the groups (*p* = 0.68; OR = 1.26, 95% CI = 0.37 – 4.40).

**The number of EPIYA-C segments**

The EPIYA pattern of all *cagA*-positive strains from both relatives of gastric cancer patients and controls were successfully typed. The Yamaoka methodology allowed the detection of mixed strain infection. The concordance between the methods used was almost 100%. The results were confirmed by sequencing of the 3’ variable region of *cagA* in 30 randomly selected PCR products.
Four patterns of EPIYA motifs were found: AB, ABC, ABCC, and ABCCC. No Asian EPIYA-D motif was observed. The distribution of the EPIYA genotypes is shown in the Table 1.

vacA mosaicism distribution

The distribution of vacA genotypes is shown in the Table 2. In 59 cases (54.13%) the vacA genotype was s1m1, in 35 (32.11%) it was s1m2 and 6 (5.50%) s2m2. In three (2.75%) cases two vacA genotypes were observed and in six (5.50%) only the signal sequence (s1) was detected. DNA was not enough to genotype m allele in four among these cases and in two, m was not typable. In all cases with s1 strains they were genotyped as s1b, except in one case who was colonized by s1a and s1b strains.

| EPIYA Genotype | Control group n (%) | Gastric cancer relatives n (%) | Siblings (n (%)) | Offspring (n (%)) |
|----------------|---------------------|-------------------------------|-----------------|-----------------|
| EPIYA-AB       | 03 (7.0)            | 0                             | 0               | 0               |
| EPIYA-ABC      | 32 (74.4)           | 09 (60.0)                     | 20 (55.5)       |                 |
| EPIYA-ABCC     | 07 (16.3)           | 04 (26.7)                     | 12 (33.2)       |                 |
| EPIYA-ABCCC    | 01 (2.3)            | 01 (6.7)                      | 02 (5.6)        |                 |
| EPIYA-ABC + ABCC | 0                  | 01 (6.7)                      | 02 (5.6)        |                 |
| Total          | 43 (100.0)          | 15 (100.0)                    | 36 (100.0)      |                 |

1Only vacA s1 genotype was identified in 6 cases (1 control, 2 siblings and 3 offsprings of gastric cancer relatives); Mixed infection by s1m1 and s2m2 or s1m1 and s1m2 (two cases).
Infection by the most toxigenic vacA genotype (s1m1) was more frequently observed in the gastric cancer relatives (65.45%) than in the controls (47.92%). When s and m alleles were individually evaluated, no difference in the frequency of s1 allele was observed between the groups, but m1 allele was more frequently observed in the gastric cancer relatives.

Association among the number of EPIYA-C motifs and the vacA s1m1 genotype and family history of gastric cancer

The relatives of gastric cancer patients were significantly and independently more frequently colonized by *H. pylori* strains with increased number CagA-EPIYA-C segments and with the most virulent s1m1 vacA genotype even after adjustment for age and gender (Table 3).

No difference was observed between siblings and offspring in respect to infection by strains containing an increased number of EPIYA-C motifs ($p = 0.98$; OR = 1.20, 95%CI = 0.30 – 4.86) and the vacA genotypes s1m1 vs. s1m2 and s2m2 ($p = 0.84$; OR = 0.92, 95%CI = 0.22 – 3.97) as shown in the Tables 1 and 2.



Table 3 Covariables associated with gastric cancer in the first-degree relatives of gastric cancer patients in comparison with subjects without family history of gastric cancer

| Variables               | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | $p$     | OR  | 95% CI | $p$|
| Gender                  | 0.27   | –   | –     | –  |
| Age                     | 0.30   | –   | –     | –  |
| >1 EPIYA-C motif        | 0.01   | 4.23 | 1.53 – 11.69 | 0.006 |
| s1m1 vacA allele        | 0.17   | 2.80 | 1.04 – 7.51 | 0.04 |

The Hosmer-Lemeshow test was fit (8 degrees of freedom, $p > 0.20$, with 10 steps).

Infection with CagA strains possessing higher number of EPIYA-C segments has been associated with precancerous gastric lesions and gastric cancer in Caucasian [11-13,30] and Brazilian populations [15].

It is well established that *H. pylori* infection is predominantly acquired in childhood and that the infection often persists for life unless treated. Epidemiological data and genetic analysis of *H. pylori* strains have demonstrated that the strains are usually acquired within the family. In fact, infected mother and infected siblings are the main risk factors for the acquisition of the infection [33,34] and genetic fingerprint methods have demonstrated genetic homogeneity in the *H. pylori* strains within the families. Based on these findings and the results of the present study, we may hypothesize that first degree relatives of gastric cancer patients may share more virulent *H. pylori* strains that may increase the risk of gastric cancer.

As noted above, first-degree relatives of gastric cancer patients also share the same or similar genetic background that may increase the risk of gastric cancer. Polymorphisms in genes coding pro-inflammatory cytokines, such as interleukin 1 beta (IL-1β), interleukin-1 receptor antagonist (IL1Ra) and tumor necrosis factor-alpha (TNF-α) are accepted as risk factors of gastric cancer, depending on the geographic region [35-39]. It has also been demonstrated that having increasing number of pro-inflammatory genotypes [36,37], as well as a
concomitant infection by more virulent \textit{H. pylori} strains progressively increases the risk of gastric precancerous lesions and cancer [39].

\subsection*{Conclusions}

In conclusion, we demonstrated that relatives of gastric cancer patients are more frequently colonized by the most virulent \textit{H. pylori} cagA and vacA genotypes, which may, in addition to human genetic predispositions, further increase their risk of gastric cancer, thus providing additional reasons to better understand these infections and perhaps their targeted eradicative treatment.

\subsection*{Competing interests}

The authors declare no-conflict-of-interest.

\subsection*{Authors’ contributions}

DMMQ supervised laboratory work and analyzed the data critical writing and reviewing manuscript. SAB performed DNA extraction, PCR and sequencing and statistical analysis, GAR and AAML performed critical analysing of the data and reviewing of the manuscript. LLB桓 participated in conception, design, implementation, coordination of the study and contributed to manuscript writing critical writing and reviewing. All authors have read and approved the final version of the manuscript.

\subsection*{Acknowledgements}

This work was supported by Instituto Nacional de Ciências e Tecnologia em Biomedicina do Semiárido Brasileiro (INCT) and CNPq, Brazil. We are grateful to Professor Barry J Marshall for critical reading of the manuscript.

\subsection*{References}

1. Parsonnet J, Friedman GD, Vandersteen DO: \textit{Helicobacter pylori} and the risk of gastric carcinoma. \textit{N Engl J Med} 1991, 251:1127–1131.

2. Brenner H, Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G: Individual and joint contribution of family history and \textit{Helicobacter pylori} infection to the risk of gastric cancer. \textit{Cancer} 2000, 882:74–79.

3. Uemura N, Okamoto S: Effect of \textit{Helicobacter pylori} eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. \textit{Gastroenterol Clin North Am} 2000, 29:819–827.

4. Chang YW, Han YS, Lee DK, Kim HJ, Lim HS, Moon JS, et al: Role of \textit{Helicobacter pylori} infection in the development of gastric cancer. \textit{Cancer} 2000, 882:74–79.

5. Jablonowska M, Chlumska A: Genetic factors in the development of gastric precancerous lesions – a role of \textit{Helicobacter pylori}? \textit{Int J Cancer} 2001, 95:477–481.

6. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS: Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by \textit{Helicobacter pylori}. \textit{Proc Natl Acad Sci USA} 1999, 96:14559–14564.

7. Odentbeat S, Püh J, Schedinberg B, Gelrand E, Fischer W, Haas R: Translocation of \textit{Helicobacter pylori} CagA into gastric epithelial cells by type IV secretion. \textit{Science} 2000, 287:1497–1500.

8. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, et al: SHP-2 tyrosine phosphatase as an intracellular target of \textit{Helicobacter pylori} CagA protein. \textit{Science} 2002, 295:683–686.

9. Naito M, Yamaizumi T, Tsutsumi R, Hashiguchi H, Otoke K, Yamazaki S, et al: Influence of EPIYA-repeat polymorphism on the phosphorylation-dependent biological activity of \textit{Helicobacter pylori} CagA. \textit{Gastroenterology} 2006, 130:1181–1190.

10. Hatakeyama M: Oncogenic mechanisms of the \textit{Helicobacter pylori} CagA protein. \textit{Nat Rev Cancer} 2004, 4:688–694.

11. Argent RH, Hale JL, El-Omar EM, Atherton JC: Differences in \textit{Helicobacter pylori} CagA tyrosine phosphorylation motif patterns between western and East Asian strains, and influences on interleukin-8 secretion. \textit{J Med Microbiol} 2008, 57:1062–1067.

12. Yamaoka Y, El-Zimaity HM, Gutierrez OF, Figura N, Kim JK, Kodama T, et al: Relationship between the cagA 3 ’ repeat region of \textit{Helicobacter pylori}, gastric histology, and susceptibility to low pH. \textit{Gastroenterology} 1999, 117:342–349.

13. Basso D, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, et al: Clinical relevance of \textit{Helicobacter pylori} cagA and vacA gene polymorphisms. \textit{Gastroenterology} 2008, 135:91–99.

14. Sciscioni LA, Correa P, Peek RM, Camargo MC, Piazzuelo MB, Romero-Gallo J, et al: CagA C-terminal variations in \textit{Helicobacter pylori} strains from Colombian patients with gastric precancerous lesions. \textit{Clin Microbiol Infect} 2010, 16:369–378.

15. Batista SA, Rocha GA, Rocha AM, Saravia IE, Cabral MM, Oliveira RC, et al: Higher number of \textit{Helicobacter pylori} CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. \textit{BMCMicrobiol} 2011, 11:561.

16. Atherton JC, Gao P, Peek RM Jr, TURNUMSU MK, BäSER MJ, COVER TL: Mosaicism in vacuolating cytotoxin alleles of \textit{Helicobacter pylori}. Association of specific vacA types with cytotoxic prediction and pepsin ulceration. \textit{J Biol Chem} 1995, 270:17771–17777.

17. Willhite DC, Blanken SR: \textit{Helicobacter pylori} vacuolating cytotoxin induces activation of the proapoptotic enters cells, localizes to the mitochondria, and induces mitochondrial membrane permeability changes correlated to toxin channel activity. \textit{Cell Microbiol} 2004, 6:143–154.

18. Yamaoka Y, Wada A, Kumatari A, Nakagawa I, Funao J, Nakayama M, et al: \textit{Helicobacter pylori} vacuolating cytotoxin induces activation of the proapoptotic proteins Bax and Bak, leading to cytochrome c release and cell death, independent of vacuolization. \textit{J Biol Chem} 2006, 281:11250–11259.

19. Ashour AA, Magalhães PP, Collares GB, de Gusmão VR, Queiroz AQ: \textit{Helicobacter pylori} vacuolating cytotoxin induces activation of the proapoptotic proteins Bax and Bak, leading to cytochrome c release and cell death, independent of vacuolization. \textit{J Biol Chem} 2006, 281:11250–11259.

20. Motta CR, Cunha MP, Queiroz DM, Cruz WW, Guerra EJ, Mota RM, et al: Gastric precancerous lesions and \textit{Helicobacter pylori} infection in relatives of gastric cancer patients from northeastern Brazil. \textit{Digestion} 2008, 78:83–8.

21. Argent RH, Thomas RJ, Aviles-Jimenez F, Letley DP, Lindb MC, El-Omar EM, Atherton JC: \textit{Toxigenic Helicobacter pylori} infection precedes hypochlorhydria in cancer relatives, and \textit{H. pylori} evolves in these families. \textit{Clin Canc Res} 2008, 14:2227–2235.

22. Dixon MF, Genta RM, Yardley JH, Correa P: \textit{Helicobacter pylori} infection by Using Polymerase Chain-Reaction. The updated Sydney System. \textit{International Workshop on the Histopathology of Gastritis,} \textit{Helicobacter,} \textit{Correa P,} \textit{J Biol Chem} 1996, 270:11533–11538.

23. Monteiro MA, Chan KH, Rasko DA, Taylor DE, Zheng PY, Appelmelk BJ, et al: Simultaneous expression of type 1 and type 2 Lewis blood group antigens by \textit{Helicobacter pylori} lipopolysaccharides. Molecular mimicry between \textit{h. pylori} lipopolysaccharides and human gastric epithelial cell surface glycoconjugates. \textit{J Biol Chem} 1998, 273:11533–11543.

24. Clayton CL, K linthous H, Coates PJ, Morgan DD, Taubazhali S: Sensitive Detection of \textit{Helicobacter pylori} by Using Polymerase Chain-Reaction. \textit{J Clin Microbiol} 2002, 40:192–200.

25. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneberger P, De Boer W, et al: Clinical relevance of the cagA, vacA, and iceA status of \textit{Helicobacter pylori}. \textit{Gastroenterology} 1998, 115:58–66.

26. Atherton JC, Cover TL, Wells RJ, Morales MR, Hawley CJ, BäSER MJ: Simple accurate PCR-based system for typing vacuolating cytotoxin alleles of \textit{Helicobacter pylori}. \textit{J Clin Microbiol} 1999, 37:2979–2982.
27. Kelly SM, Pitcher MC, Farmery SM, Gibson GR: Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994, 107:1671–1674.
28. Peek RM Jr, Miller GG, Tham KT, Perez-Perez GI, Cover TL, Atherton JC, et al: Detection of Helicobacter pylori gene expression in human gastric mucosa. J Clin Microbiol 1995, 33:26–32.
29. Yamaoka Y, Kodama T, Kashima K, Graham DY, Sepulveda AR: Variants of the 3’ region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J Clin Microbiol 1998, 36:2258–2263.
30. Argent RH, Kidd M, Owen RJ, Thomas RJ, Limb MC, Atherton JC: Determinants and consequences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology 2004, 127:514–523.
31. Hosmer DW, Lemeshow S (Eds): Applied Logistic Regression, JH. New York: Wiley Interscience Publication; 2000.
32. Hatakeyama M: Anthropological and clinical implications for structural diversity of the Helicobacter pylori CagA oncoprotein. Cancer Sci 2011, 102:36–43.
33. Rocha GA, Rocha AM, Silva LD, Santos A, Bocewicz AC, Queiroz R, Rde M, et al: Transmission of Helicobacter pylori infection in families of preschool-aged children from Minas Gerais, Brazil, Trop Med Int Health 2003, 8:987–991.
34. Kivi M, Johannson AL, Reilly M, Tindberg Y: Helicobacter pylori status in family members as risk factors for infection in children. Epidemiol Infect 2005, 133:645–652.
35. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398–402.
36. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine genes polymorphisms. Gastroenterology 2003, 124:1193–1201.
37. Machado JC, Figueiredo C, Canedo P, Pharoah P, Seruca R, Carvalho R, et al: A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003, 125:364–371.
38. Rocha GA, Guerra JB, Rocha AMC, Saraiva IEB, da Silva DA, de Oliveira CA, et al: IL1RN polymorphic gene and cagA-positive status independently increase the risk of noncardia gastric carcinoma. Int J Cancer 2005, 115:678–683.
39. Figueiredo C, Machado JC, Pharoah P, Seruca R, Souza S, Carvalho R, et al: Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002, 94:1680–1687.

doii:10.1186/1471-230X-12-107
Cite this article as: Queiroz et al: Higher frequency of cagA EPIYA-C Phosphorylation Sites in H. pylori strains from first-degree relatives of gastric cancer patients. BMC Gastroenterology 2012 12:107.